SFG–iMC-CD123.zeta

N/A

Report date: 2025/01/26 17:51:38

Base Information

Drug NameSFG–iMC-CD123.zeta

Drug Alias NameAnti-CD123 CAR T-cell therapy (Bellicum)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A